undamentalytics Newsletter
Sign in

Biote Corp. income statement

In fiscal 2025, Biote Corp. reported revenue of $192m, down 2.5% on the year before, operating income of $35.6m (a 18.5% margin) and net income of $27.0m, or $0.74 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue139165185197192184
Selling, general and administrative4917199107102111
Operating income35−6129323615
Income before tax332−013810
Income tax003163
Net income11−133276
Diluted EPS—−$0.12$0.13$0.09$0.74$0.16
Diluted shares (average)—8m26m34m37m36m
EBITDA36−5932353918

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: BTMD vs OGIBTMD vs KMDABTMD vs CRONAMRN vs BTMD

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Biote Corp.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Biote Corp.